Articles & Blogs

Perspectives on Anti-Infective Drug Development from Experts in the Trenches

Recent Articles & Blogs

Blog
Article
Building a leader in infectious diseases, Ankit Mahadevia, President and CEO, Spero Therapeutics
By:
Biotech 2050 Podcast:
July 13, 2021
September 8, 2022
Read more
Blog
Article
PASTEUR Act Reintroduced - A Bold, Potentially Transformative Approach to Addressing the Threat of Antimicrobial Resistance
By:
Cristina Larkin and David Melnick, MD
June 17, 2021
September 8, 2022
Read more
Blog
Article
Comprehensive Policy for Infection: There Has Never Been a Better Time
By:
Timmerman Report
March 24, 2021
September 8, 2022
Read more
Blog
Article
Getting Ready for the Next Pandemic with a Comprehensive Response
By:
Timmerman Report
November 5, 2020
September 8, 2022
Read more
Blog
Article
Playing To Win: Scenario Planning For Binary Readouts In Biotech
By:
LifeSciVC
November 5, 2020
September 8, 2022
Read more
Blog
Article
Playing the Long Game for Antibiotic R&D
By:
Timmerman Report
November 5, 2020
September 8, 2022
Read more
Blog
Article
COVID-19 Has Made Hospital Avoidance a Critical Component of Good Care
By:
Nayiri Baljian and Jennifer Reese
August 11, 2020
September 8, 2022
Read more
Blog
Article
SPR720: Listening to Patients, Clinicians and Regulators, and Advancing Forward
By:
Troy Lister, PhD, Sue Stokes, PhD, and David Melnick, MD
June 11, 2020
September 8, 2022
Read more
Blog
Article
BioBoss Podcast with Ankit Mahadevia: CEO of Spero Therapeutics
By:
BioBoss Podcast
April 27, 2020
September 8, 2022
Read more
Blog
Article
Navigating The Unknown: Practical Thoughts On A Team That Can Rise To The Occasion
By:
LifeSciVC
April 2, 2020
September 8, 2022
Read more
Blog
Article
SPR994: A Long Shot, With Lots Of Twists And Turns To Phase III
By:
LifeSciVC
April 2, 2020
September 8, 2022
Read more
Blog
Article
The Balancing Act: Taking A Systematic Approach To Hard Decisions In Times Of Rapid Change
By:
LifeSciVc
April 2, 2020
September 8, 2022
Read more
Blog
Article
Thinking Ahead: Building a Broad Arsenal Against Infectious Disease
By:
Timmerman Report
April 2, 2020
September 8, 2022
Read more
Blog
Article
Evidence Matters: Importance of Tebipenem HBr Oral-Only Trial Design for Clinical Utility and Commercial Uptake Potential
By:
Cristina Larkin and David Melnick, MD
February 26, 2020
September 8, 2022
Read more
Blog
Article
Beyond the headlines: Why we are excited about our pipeline and the future for patients needing effective treatments for infections
By:
Ankit Mahadevia, MD
January 9, 2020
September 8, 2022
Read more
Blog
Article
New Options for Patients: New Preliminary Clinical Data on SPR720 and Our Stepwise Plan to Explore the Broad Potential of SPR720 in NTM
By:
David Melnick, MD
December 6, 2019
September 8, 2022
Read more
Blog
Article
Exciting Independent Review Committee Recommendation Announced Today Based on Positive Interim PK Data from SPR994 ADAPT-PO Phase 3 Clinical Trial
By:
David Melnick, MD
October 3, 2019
September 8, 2022
Read more
Blog
Article
NASDAQ Spotlight Interview of Spero CEO, Ankit Mahadevia, MD
By:
Nasdaq Spotlight
September 25, 2019
September 8, 2022
Read more
Blog
Article
New Strategic Alliances to Build Industry Leading Pipeline: Partnerships with Gates MRI and the Novo REPAIR Impact Fund Validate and Accelerate Development of SPR720
By:
Troy Lister
July 2, 2019
September 8, 2022
Read more
Blog
Article
SPR994’s Value Proposition: A dive into how SPR994, an oral carbapenem, could benefit patients, payers, and investors
By:
Joel Sendek
May 15, 2019
September 8, 2022
Read more
Blog
Article
Hiring: Using Your Team To Build A Team
By:
LifeSciVC:
March 12, 2019
September 8, 2022
Read more
Blog
Article
If You Build It, Will They Come? Addressing The Value Equation
By:
LifeSciVC:
March 12, 2019
September 8, 2022
Read more
Blog
Article
Why Are We Losing Oral Antibiotics for the Treatment of cUTI?
By:
Ian Critchley, Ph.D.
March 6, 2019
September 8, 2022
Read more
Blog
Article
Designing the Right Clinical Trial to Yield the Greatest Value
By:
David Melnick, MD and Cristina Larkin
January 4, 2019
September 8, 2022
Read more
Blog
Article
Non-tuberculous Mycobacterial Disease: The Unmet Need and a Possible New Solution with SPR720
By:
Ankit Mahadevia, MD and Cristina Larkin
November 5, 2018
September 8, 2022
Read more
Blog
Article
Boston-area companies bet on antibiotic development, even as big drug makers step back
By:
STAT News:
October 18, 2018
September 8, 2022
Read more
Blog
Article
Meet the BBJ's 2018 40 Under 40 honorees
By:
Boston Business Journal:
October 18, 2018
September 8, 2022
Read more
Blog
Article
Antibiotic Opportunity? Spero's Ankit Mahadevia on The Long Run Podcast
By:
The Timmerman Report:
October 18, 2018
September 8, 2022
Read more
Blog
Article
Investing in Antibiotic Companies: Why the Sector is Compelling Now
By:
Joel Sendek
October 1, 2018
September 8, 2022
Read more
Blog
Article
Spero’s New Inter-agency Collaboration
By:
Ankit Mahadevia
July 16, 2018
September 8, 2022
Read more
Blog
Article
Beyond the CEO: Building An Effective Leadership Team
By:
LifeSciVC
June 10, 2018
September 8, 2022
Read more
Blog
Article
Advancing Spero’s Potentiator Platform
By:
Melissa Stundick, Senior Vice President, Business Development
May 30, 2018
September 8, 2022
Read more
Blog
Article
Billion Dollar Antibiotics in the Era of Stewardship:
By:
Cristina Larkin, David Melnick, and Keith A. Rodvold
April 25, 2018
September 8, 2022
Read more
Blog
Article
Antibiotic Drug Development:
By:
Ankit Mahadevia, David Melnick, and Paul Ambrose
March 26, 2018
September 8, 2022
Read more
Blog
Article
Biotech startups: What you need to bring your dream to fruition
By:
GoDaddy
January 23, 2018
September 8, 2022
Read more
Blog
Article
Spero Therapeutics Raises $30M Series A, Plans Antibiotic Clinical Trials in 2016
By:
Dow Jones
October 30, 2017
September 8, 2022
Read more
Blog
Article
Spero Completes $30 Million Financing
By:
Marketwatch
October 30, 2017
September 8, 2022
Read more
Blog
Article
Spero Achieves First Milestone Payment in Anti-Infective Partnership with Roche
By:
First Word Pharma
October 30, 2017
September 8, 2022
Read more
Blog
Article
Spero Therapeutics Raised $30M in Series B Funding
By:
Finsmes
October 30, 2017
September 8, 2022
Read more
Blog
Article
Merck & Co. (MRK), New England Patriots Owner Wager $30 Million on Cambridge Startup, Spero
By:
BioSpace
October 30, 2017
September 8, 2022
Read more
Blog
Article
Spero Therapeutics fetches $30 mln Series A
By:
PE Hub
October 30, 2017
September 8, 2022
Read more
Blog
Article
Spero Achieves First Milestone Payment In Anti-Infective Partnership With Roche (RHHBY)
By:
BioSpace
October 30, 2017
September 8, 2022
Read more
Blog
Article
Spero Eyes First Trial, Gets $30M More to Battle Drug-Resistant Bugs
By:
Xconomy
October 28, 2017
September 8, 2022
Read more
Blog
Article
Spero Therapeutics: Remodeling Antibiotics
By:
START-UP
October 28, 2017
September 8, 2022
Read more
Blog
Article
Google Leads $51M Investment in Startup Tackling Drug-Resistant Bacteria
By:
R & D Magazine
October 28, 2017
September 8, 2022
Read more
Blog
Article
The Daily Startup: Spero Raises $30M to Fight Drug-Resistant Bacteria
By:
Wall Street Journal
October 28, 2017
September 8, 2022
Read more
Blog
Article
Financings
By:
BioWorld Today
October 28, 2017
September 8, 2022
Read more
Blog
Article
Management tracks
By:
BioCentury
October 28, 2017
September 8, 2022
Read more
Blog
Article
Spero Therapeutics Catches Roche’s Eye with a New Way to Target Drug-Resistant Bacterial Infections
By:
MedCity News
October 28, 2017
September 8, 2022
Read more
Blog
Article
Roche returns to antibiotic research as superbug threat grows
By:
Reuters
October 28, 2017
September 8, 2022
Read more
Blog
Article
Antibiotics funding hike gets mixed reception
By:
Nature News and Views
October 28, 2017
September 8, 2022
Read more
Blog
Article
Pushing Forward with Collaborative R&D Models in Biotech
By:
Forbes/LifeSciVC Blog
October 28, 2017
September 8, 2022
Read more
Blog
Article
The Daily Startup: Spero Raises $30M to Fight Drug-Resistant Bacteria
By:
WSJ Venture Capital
October 28, 2017
September 8, 2022
Read more
Blog
Article
News from ASM 2017
By:
BioWorld
October 28, 2017
September 8, 2022
Read more
Blog
Article
Spero Raises $51.7M In Series C
By:
BioCentury
October 28, 2017
September 8, 2022
Read more
Blog
Article
Five things you need to know today, and the value of economic incentives
By:
Boston Business Journal
October 28, 2017
September 8, 2022
Read more
Blog
Article
Building A Stronger Ecosystem to Combat Antimicrobial Resistance
By:
LifeSciVC
October 28, 2017
September 8, 2022
Read more
Blog
Article
The Potentiator: Spero Therapeutics gets $30M to up potency of existing antibiotics
By:
MedCity News
October 28, 2017
September 8, 2022
Read more
Blog
Article
ASM Microbe 2016: Candidate Antimicrobials, Enhancers, Potentiators, Combos Plus New Probe
By:
Microbe Magazine
October 28, 2017
September 8, 2022
Read more
Blog
Article
There’s Big Money Again in Saving Humanity With Antibiotics
By:
Bloomberg
October 28, 2017
September 8, 2022
Read more
Blog
Article
Troy Lister – Bug Battler: Medicinal chemist takes unconventional approach to battling bacteria
By:
Chemical & Engineering News Talented 12
October 28, 2017
September 8, 2022
Read more
Blog
Article
Why More Incentives Are Needed To Tackle Antibiotic Resistance
By:
Life Science Leader
October 28, 2017
September 8, 2022
Read more
Blog
Article
Spero Therapeutics announces $51.7 million in new financing
By:
Boston Globe
October 28, 2017
September 8, 2022
Read more
Blog
Article
Chutes & Ladders
By:
FierceBiotech
October 28, 2017
September 8, 2022
Read more
Blog
Article
Spero Therapeutics raises $30M to support its drug delivery platform targeting Gram-negative bacteria
By:
FierceDrugDelivery
October 28, 2017
September 8, 2022
Read more
Blog
Article
The superbug incentive
By:
The Boston Globe
October 28, 2017
September 8, 2022
Read more
Blog
Article
Roche and Spero Sign Into Antibiotics Partnership
By:
Bioresearch Online
October 28, 2017
September 8, 2022
Read more
Blog
Article
Drug industry warming to antibiotics, but resistance outpaces new products
By:
STAT
October 28, 2017
September 8, 2022
Read more
Blog
Article
Investors Back Bug Fighters
By:
BioWorld Insight
October 28, 2017
September 8, 2022
Read more
Blog
Article
Look Beyond The Headlines: Tackling Ever-Present Challenge Of Antimicrobial Resistance
By:
LifeSciVC.com
October 28, 2017
September 8, 2022
Read more
Blog
Article
News from ECCMID
By:
BioWorld
October 28, 2017
September 8, 2022
Read more
Blog
Article
Biota Pharmaceuticals Sells Antibiotic Program to Spero Therapeutics
By:
Genetic Engineering & Biotechnology News
October 28, 2017
September 8, 2022
Read more
Blog
Article
Spero closes $30M series B round
By:
BioCentury Extra
October 28, 2017
September 8, 2022
Read more
Blog
Article
Execs On The Move, June 2017
By:
In Vivo
October 28, 2017
September 8, 2022
Read more
Blog
Article
Cambridge biotech Spero bags $51M as GV joins latest round
By:
Boston Business Journal
October 28, 2017
September 8, 2022
Read more
Blog
Article
Drug resistance specter fact of life for antibiotics
By:
BioWorld
October 28, 2017
September 8, 2022
Read more
Blog
Article
Spero Emerges with $3M, Backing from Roche, and Plans to Disarm Bugs
By:
Xconomy
October 28, 2017
September 8, 2022
Read more
Blog
Article
Funding, Success for Life Science Startups is On the Rise – Spero Therapeutics
By:
Laboratory Equipment
October 28, 2017
September 8, 2022
Read more
Blog
Article
Dunsire Joins Xtuit to Fight Microenvironment; Spero Gets $51.7M for Antibiotics
By:
Timmerman Report
October 28, 2017
September 8, 2022
Read more
Blog
Article
Can We Save Ourselves From The End Of Antibiotics—Or Have The Superbugs Already Won?
By:
Fast Company Co Exist
October 28, 2017
September 8, 2022
Read more
Blog
Article
Racing toward the right answers: Treating gram-negative bacterial infections
By:
Healio
October 28, 2017
September 8, 2022
Read more
Blog
Article
CARB-X’s first round of grants goes to firms big and small in antimicrobial resistance fight
By:
BioWorld
October 28, 2017
September 8, 2022
Read more
Blog
Article
Atlas startup Spero gets $30M to give new life to old antibiotics
By:
Boston Business Journal
October 28, 2017
September 8, 2022
Read more
Blog
Article
Antibiotic Incentives Helped Spero Get Where It Is Today
By:
The Pink Sheet
October 28, 2017
September 8, 2022
Read more
Blog
Article
AMPs take aim at AMRs as biopharma seeks new solutions to resistance
By:
BioWorld Insight
October 28, 2017
September 8, 2022
Read more
Blog
Article
Promiliad, Spero Therapeutics, University of Connecticut deal
By:
BioCentury
October 28, 2017
September 8, 2022
Read more
Blog
Article
Growth Phase: Avoiding Vertigo During the Ride Up
By:
LifeSciVC.com
October 28, 2017
September 8, 2022
Read more
Blog
Article
Agencies push bug drug pipeline but development lacks market pull
By:
BioWorld
October 28, 2017
September 8, 2022
Read more
Blog
Article
Meet Spero, a Biotech Hopeful with Roche’s Blessing and a Novel Antiobiotic
By:
FierceBiotech
October 28, 2017
September 8, 2022
Read more
Blog
Article
Atlas Venture’s Newest Stab at an Antibiotics Biotech Comes Out of Stealth
By:
Boston Business Journal
October 28, 2017
September 8, 2022
Read more
Blog
Article
Patriots owner Kraft teams up on a $30M antibiotics round for Spero
By:
FierceBiotech
October 28, 2017
September 8, 2022
Read more
Blog
Article
U.S.–U.K. Alliance Targets World’s Deadliest Superbugs
By:
Managed Care
October 28, 2017
September 8, 2022
Read more
Blog
Article
With $30M, Spero Broadens Fight Against Drug-Resistant Bugs
By:
Xconomy
October 28, 2017
September 8, 2022
Read more
Blog
Article
Startup Spero Makes Antibiotics Pact with Roche
By:
GEN News
October 28, 2017
September 8, 2022
Read more
Blog
Article
Spero Therapeutics Licenses Dihydrofolate Reductase Inhibitors from Promiliad Biopharma
By:
BioWorld Today
October 28, 2017
September 8, 2022
Read more
Blog
Article
Spero shoots through series C target
By:
Global University Venturing
October 28, 2017
September 8, 2022
Read more
Blog
Article
Spero pads syndicate, lands $51.7M series C for pipeline of antibacterials
By:
BioWorld Today
October 28, 2017
September 8, 2022
Read more
Blog
Article
Glaxo, Atlas syndicate bankrolls Spero’s drive into the clinic with $30M round
By:
FierceBiotech
October 28, 2017
September 8, 2022
Read more
Blog
Article
China rises as a biotech powerhouse, developing drugs to treat the world
By:
STAT
October 28, 2017
September 8, 2022
Read more
Blog
Article
Google’s venture arm leads Spero’s $51.7M round for R&D work on a pipeline of new antibiotics
By:
Endpoints
October 28, 2017
September 8, 2022
Read more

Sign up to receive news and announcements.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.